| Abbvie (3) |  |
| Alkaloid (11) | |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| Eisai company (3) | |
| Emergent biosolutions (4) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Merck & co (4) | |
| Novartis (22) | |
| Pfizer (10) | |
| Regeneron pharmaceuticals (3) | |
| Sanofi (5) | |
Dr Sarah Hatsell and her colleagues at Regeneron found that the overactivity of the mutant receptor is caused by its altered response to the signalling molecule Activin-A this molecule normally makes AVCR1 less active,
Regeneron is currently performing preclinical safety testing and may eventually conduct clinical trials if a safe clinical trial can be designed.
'We are very fortunate and grateful that not only did Regeneron make this basic science discovery,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011